Drug interactions
Brentuximab + Cenobamate
Severity: Minor
Brentuximab and Cenobamate: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Cenobamate induces CYP3A4 and may reduce exposure to MMAE, the cytotoxic component released from brentuximab vedotin. Lower MMAE exposure could theoretically reduce antitumor efficacy.
What this interaction means in plain words
Brentuximab and Cenobamate have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Brentuximab belongs to Oncology; Cenobamate belongs to Central Nervous System.
Why it happens
CYP3A4 induction by cenobamate increases MMAE clearance.
What to do
No empiric dose increase of brentuximab is recommended. Monitor disease response.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Brentuximab and Cenobamate, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Brentuximab
- Bleomycin + Brentuximab Contraindicated
- Brentuximab + Dengue vaccine Major
- Brentuximab + Etrasimod Major
- Brentuximab + Idelalisib Major
- Brentuximab + Levoketoconazole Major
- Brentuximab + Nefazodone Major
Other interactions of Cenobamate
Frequently asked questions
Can I take Brentuximab with Cenobamate?
MediHelp rates the interaction as minor. Brentuximab and Cenobamate have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Cenobamate induces CYP3A4 and may reduce exposure to MMAE, the cytotoxic component released from brentuximab vedotin. Lower MMAE exposure could theoretically reduce antitumor efficacy.
How serious is the interaction between Brentuximab and Cenobamate?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No empiric dose increase of brentuximab is recommended. Monitor disease response.
What other medicines interact with Brentuximab?
MediHelp also lists interactions of Brentuximab with, for example, Bleomycin, Dengue vaccine, Etrasimod. The full list is on the Brentuximab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
